These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 8455942

  • 1. Suppression of oncogene-induced transformation by a deletion mutant of c-jun.
    Brown PH, Alani R, Preis LH, Szabo E, Birrer MJ.
    Oncogene; 1993 Apr; 8(4):877-86. PubMed ID: 8455942
    [Abstract] [Full Text] [Related]

  • 2. Mechanism of action of a dominant-negative mutant of c-Jun.
    Brown PH, Chen TK, Birrer MJ.
    Oncogene; 1994 Mar; 9(3):791-9. PubMed ID: 8108121
    [Abstract] [Full Text] [Related]

  • 3. B-ATF functions as a negative regulator of AP-1 mediated transcription and blocks cellular transformation by Ras and Fos.
    Echlin DR, Tae HJ, Mitin N, Taparowsky EJ.
    Oncogene; 2000 Mar 30; 19(14):1752-63. PubMed ID: 10777209
    [Abstract] [Full Text] [Related]

  • 4. The inhibitory activity of a transdominant c-jun mutant fused to the ligand binding domain of the estrogen receptor.
    Kim S, Brown PH, Birrer MJ.
    Oncogene; 1996 Mar 07; 12(5):1043-53. PubMed ID: 8649795
    [Abstract] [Full Text] [Related]

  • 5. Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes.
    Li JJ, Rhim JS, Schlegel R, Vousden KH, Colburn NH.
    Oncogene; 1998 May 28; 16(21):2711-21. PubMed ID: 9652737
    [Abstract] [Full Text] [Related]

  • 6. Differential induction of c-fos and c-jun proto-oncogenes and AP-1 activity by tumor promoter 12-O-tetradecanoyl phorbol 13-acetate in cells at different stages of tumor promotion in vitro.
    Wu WS, Lin JK, Wu FY.
    Oncogene; 1992 Nov 28; 7(11):2287-94. PubMed ID: 1437150
    [Abstract] [Full Text] [Related]

  • 7. Structure and transcriptional regulation of BKJ, a novel AP-1 target gene activated during jun- or fos-induced fibroblast transformation.
    Hartl M, Bister K.
    Oncogene; 1998 Dec 03; 17(22):2901-13. PubMed ID: 9879996
    [Abstract] [Full Text] [Related]

  • 8. Transformation suppressor activity of a Jun transcription factor lacking its activation domain.
    Lloyd A, Yancheva N, Wasylyk B.
    Nature; 1991 Aug 15; 352(6336):635-8. PubMed ID: 1907719
    [Abstract] [Full Text] [Related]

  • 9. Activation and inhibition of the AP-1 complex in human breast cancer cells.
    Chen TK, Smith LM, Gebhardt DK, Birrer MJ, Brown PH.
    Mol Carcinog; 1996 Mar 15; 15(3):215-26. PubMed ID: 8597534
    [Abstract] [Full Text] [Related]

  • 10. Transformation by Jun: requirement for leucine zipper, basic region and transactivation domain and enhancement by Fos.
    Morgan IM, Ransone LJ, Bos TJ, Verma IM, Vogt PK.
    Oncogene; 1992 Jun 15; 7(6):1119-25. PubMed ID: 1594243
    [Abstract] [Full Text] [Related]

  • 11. AP-1 transrepressing retinoic acid does not deplete coactivators or AP-1 monomers but may target specific Jun or Fos containing dimers.
    Suzukawa K, Colburn NH.
    Oncogene; 2002 Mar 28; 21(14):2181-90. PubMed ID: 11948401
    [Abstract] [Full Text] [Related]

  • 12. c-Jun and c-Fos cooperate with STAT3 in IL-6-induced transactivation of the IL-6 respone element (IRE).
    Schuringa JJ, Timmer H, Luttickhuizen D, Vellenga E, Kruijer W.
    Cytokine; 2001 Apr 21; 14(2):78-87. PubMed ID: 11356008
    [Abstract] [Full Text] [Related]

  • 13. Transcriptional regulation of intercellular adhesion molecule 1 by phorbol ester in human neuroblastoma cell line SK-N-SH involves jun- and fos-containing activator protein 1 site binding complex(es).
    Farina AR, Cappabianca L, Mackay AR, Tiberio A, Tacconelli A, Tessitore A, Frati L, Martinotti S, Gulino A.
    Cell Growth Differ; 1997 Jul 21; 8(7):789-800. PubMed ID: 9218873
    [Abstract] [Full Text] [Related]

  • 14. Dominant-negative mutants of cJun inhibit AP-1 activity through multiple mechanisms and with different potencies.
    Brown PH, Kim SH, Wise SC, Sabichi AL, Birrer MJ.
    Cell Growth Differ; 1996 Aug 21; 7(8):1013-21. PubMed ID: 8853897
    [Abstract] [Full Text] [Related]

  • 15. Jun DNA-binding is modulated by mutations between the leucines or by direct interaction of fos with the TGACTCA sequence.
    Hirai S, Yaniv M.
    New Biol; 1989 Nov 21; 1(2):181-91. PubMed ID: 2562220
    [Abstract] [Full Text] [Related]

  • 16. Heterodimerization with c-Fos is not required for cell transformation of chicken embryo fibroblasts by Jun.
    Hughes M, Sehgal A, Hadman M, Bos T.
    Cell Growth Differ; 1992 Dec 21; 3(12):889-97. PubMed ID: 1472469
    [Abstract] [Full Text] [Related]

  • 17. Fos and Jun form cell specific protein complexes at the neuropeptide tyrosine promoter.
    Jalava A, Mai S.
    Oncogene; 1994 Aug 21; 9(8):2369-75. PubMed ID: 8036020
    [Abstract] [Full Text] [Related]

  • 18. fos-jun Conspiracy: implications for the cell.
    Verma IM, Ransone LJ, Visvader J, Sassone-Corsi P, Lamph WW.
    Princess Takamatsu Symp; 1989 Aug 21; 20():119-26. PubMed ID: 2518685
    [Abstract] [Full Text] [Related]

  • 19. Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73.
    Smeal T, Binetruy B, Mercola DA, Birrer M, Karin M.
    Nature; 1991 Dec 12; 354(6353):494-6. PubMed ID: 1749429
    [Abstract] [Full Text] [Related]

  • 20. Impaired induction of c-fos/c-jun genes and of transcriptional regulatory proteins binding distinct c-fos/c-jun promoter elements in activated human T cells during aging.
    Whisler RL, Chen M, Beiqing L, Carle KW.
    Cell Immunol; 1997 Jan 10; 175(1):41-50. PubMed ID: 9015187
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.